재택 주입 요법 시장 : 예측(2026-2031년)

Home Infusion Therapy Market, with a 6.29% CAGR, is projected to increase from USD 29.450 billion in 2025 to USD 42.455 billion in 2031.

The home infusion therapy market is experiencing significant and sustained growth, driven by a fundamental shift in care delivery from institutional settings to the patient's home. This model involves the administration of parenteral medications, including antibiotics, chemotherapy, biologics, pain management therapies, and nutritional support, within a patient's residence under clinical supervision. The market's expansion is propelled by a powerful convergence of patient preference, clinical efficacy, regulatory support, and technological advancement, positioning home infusion as a critical component of value-based healthcare strategies.

Core Market Drivers and Clinical Imperatives

A primary driver is the compelling array of benefits associated with home-based care. Studies consistently demonstrate high levels of patient satisfaction and positive clinical outcomes with home infusion, often comparable or superior to inpatient settings. From a patient perspective, it offers unparalleled convenience, preserving normalcy and family support while eliminating the logistical and emotional burdens of frequent hospital visits. This aligns with a clear and growing patient preference for receiving care in the comfort and privacy of their own homes whenever clinically appropriate.

Clinically, home infusion presents a direct strategy for mitigating the risk of Hospital-Acquired Infections (HAIs). By reducing or eliminating inpatient stays, it lowers patient exposure to multi-drug resistant organisms and other pathogens prevalent in healthcare facilities. This addresses a persistent challenge in acute care and is a significant motivator for providers and payers focused on improving patient safety metrics.

Demographic and epidemiological trends further solidify demand. The growing prevalence of chronic conditions requiring long-term or recurring intravenous treatment-such as certain cancers, autoimmune disorders, and infections-creates a substantial patient base. Concurrently, an aging global population and the rising incidence of mobility-impairing disorders make the logistical challenges of accessing clinic-based care more pronounced. Home infusion directly addresses these access barriers, ensuring continuity of therapy for patients with physical or geographic constraints.

Regulatory and Technological Enablers

Supportive regulatory frameworks and payment policies are accelerating market formalization and expansion. Recent updates to reimbursement structures in key markets have broadened coverage to include not only the infused drugs but also the associated professional services, nursing care, and remote monitoring required for safe home administration. This financial validation is crucial for scaling service offerings and incentivizing provider participation.

Technological innovation is enhancing the safety, efficiency, and reach of home infusion. The development of advanced, connected ambulatory infusion pumps allows for precise drug delivery and remote monitoring of therapy adherence and pump function. Integrated digital platforms facilitate better coordination among pharmacists, nurses, prescribers, and patients, streamlining the complex workflow and improving communication across the care continuum.

Market Challenges and Operational Complexities

Despite strong tailwinds, the market faces notable operational hurdles. The home infusion ecosystem is inherently complex, requiring seamless coordination among multiple stakeholders: prescribing physicians, specialty pharmacies, infusion nursing services, payers, and the patients themselves. Disconnected data systems and fragmented communication channels can lead to delays in therapy initiation, billing inaccuracies, and potential safety gaps. Ensuring rigorous patient education and maintaining robust clinical oversight outside a controlled facility environment remain paramount concerns that demand structured protocols and technological support.

Furthermore, successful implementation depends on careful patient selection. Not all patients or therapies are suitable for the home setting; criteria must include clinical stability, a safe home environment, and the patient's or caregiver's ability to manage certain aspects of care. Navigating prior authorization requirements and demonstrating cost-effectiveness to payers also present ongoing administrative challenges for providers.

Geographic Market Dynamics

North America is projected to maintain a dominant market share, serving as the most mature and advanced region for home infusion services. This leadership is underpinned by a favorable regulatory landscape that has proactively expanded reimbursement, a high prevalence of chronic diseases, a well-developed infrastructure of specialty pharmacy providers, and significant technological adoption. The presence of established pharmaceutical and medical device companies with dedicated infusion portfolios further reinforces the region's central role in driving innovation and service models.

Competitive Landscape and Strategic Outlook

The competitive environment includes a mix of large healthcare corporations, specialized infusion pharmacy networks, and hospital-affiliated providers. Key players compete on the basis of clinical expertise, geographic coverage, payer contracts, and technological integration. Strategic focus areas include the development of comprehensive disease management programs, investment in predictive analytics for patient monitoring, and the formation of strategic alliances to create integrated regional networks capable of managing the full patient journey.

In conclusion, the home infusion therapy market is transitioning from a niche alternative to a mainstream pillar of modern healthcare delivery. Its growth is structurally supported by demographic shifts, economic incentives favoring site-of-care optimization, and technological enablement. For industry experts, the critical path forward involves standardizing care protocols, advancing interoperable health IT solutions to reduce ecosystem complexity, and continuing to generate robust real-world evidence demonstrating the model's superior value in terms of patient outcomes, satisfaction, and total cost of care. The trajectory points toward continued expansion into new therapeutic areas and deeper integration with broader home-based care initiatives.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Home Infusion Therapy Market Segmentation

• By Product Type
• Infusion Pumps
• Infusion Catheters
• Intravenous IV Sets
• Others
• By Route of Administration
• Intravenous
• Subcutaneous
• By Application
• Anti-Infective Therapy
• Parenteral Nutrition
• Chemotherapy
• Pain Management Drugs
• Hydration Therapy
• Others
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HOME INFUSION THERAPY MARKET BY PRODUCT TYPE

• 5.1. Introduction
• 5.2. Infusion Pumps
• 5.3. Infusion Catheters
• 5.4. Intravenous IV Sets
• 5.5. Others

6. HOME INFUSION THERAPY MARKET BY ROUTE OF ADMINISTRATION

• 6.1. Introduction
• 6.2. Intravenous
• 6.3. Subcutaneous

7. HOME INFUSION THERAPY MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Anti-Infective Therapy
• 7.3. Parenteral Nutrition
• 7.4. Chemotherapy
• 7.5. Pain Management Drugs
• 7.6. Hydration Therapy
• 7.7. Others

8. HOME INFUSION THERAPY MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Product Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Application
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Product Type
  • 8.3.2. By Route of Administration
  • 8.3.3. By Application
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Product Type
  • 8.4.2. By Route of Administration
  • 8.4.3. By Application
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Product Type
  • 8.5.2. By Route of Administration
  • 8.5.3. By Application
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Israel
    • 8.5.4.4. Others
• 8.6. Asia Pacific
  • 8.6.1. By Product Type
  • 8.6.2. By Route of Administration
  • 8.6.3. By Application
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. India
    • 8.6.4.3. Japan
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Taiwan
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. B. Braun SE
• 10.2. Baxter International Inc.
• 10.3. Becton Dickinson Company
• 10.4. Fresenius Kabi
• 10.5. ICU Medical Inc.
• 10.6. Terumo Corporation
• 10.7. Nipro Corporation
• 10.8. KORU Medical Systems
• 10.9. CODAN Companies
• 10.10. BPL Medical Technologies

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations